Loading...
COGT logo

Cogent Biosciences, Inc.NasdaqGS:COGT Voorraadrapport

Marktkapitalisatie US$6.6b
Prijs aandeel
n/a
1Y321.8%
7D1.8%
1D1.9%
Portefeuillewaarde
​
Bekijk

Cogent Biosciences, Inc.

NasdaqGS:COGT Voorraadrapport

Marktkapitalisatie: US$6.6b

Cogent Biosciences (COGT) Aandelenoverzicht

Cogent Biosciences, Inc., een biotechnologiebedrijf in een klinische fase, richt zich op de ontwikkeling van precisietherapieën voor genetisch bepaalde ziekten. Meer informatie

Beloningen

De winst zal naar verwachting met 65.02% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd


COGT Community Fair Values

Create Narrative

See what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW499,625 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
499,625 investors already sharing narratives
View all narratives

Cogent Biosciences, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Cogent Biosciences
Historische aandelenkoersen
Huidige aandelenkoersUS$39.44
52 Week HoogtepuntUS$43.73
52 Week LaagUS$8.80
Bèta0.34
1 maand verandering27.14%
3 maanden verandering10.72%
1 Jaar Verandering321.82%
3 jaar verandering217.55%
5 jaar verandering479.15%
Verandering sinds IPO312.55%

Recent nieuws en updates

Analyseartikel • Jun 18

Cogent Biosciences (COGT) Stock Can APEX Trial Progress Justify A 10.6x P B Ratio

Cogent Biosciences (COGT) stock is in focus after the company released updated APEX trial data for bezuclastinib in advanced systemic mastocytosis, along with preclinical results for JAK2 V617F inhibitor CGT1145 at the 2026 EHA Congress. See our latest analysis for Cogent Biosciences. The latest APEX and CGT1145 data arrive as Cogent Biosciences trades at US$33.67, with recent momentum reflected in a 7.3% 7 day share price return. The 1 year total shareholder return of about 4.7x highlights...
Seeking Alpha • Jun 14

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

Summary Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications with strong clinical data. COGT holds $866.4 million in cash, supporting operations through 2028 and enabling launches in systemic mastocytosis and GIST, mitigating near-term financing risk. Bezuclastinib has demonstrated robust efficacy in nonadvanced and advanced systemic mastocytosis and second-line GIST, with three regulatory filings and positive pivotal trial results. Despite stretched valuation metrics, I see COGT as an attractive opportunity for investors willing to accept regulatory and launch risk, given its maturing clinical and commercial profile. Read the full article on Seeking Alpha

Recent updates

Analyseartikel • Jun 18

Cogent Biosciences (COGT) Stock Can APEX Trial Progress Justify A 10.6x P B Ratio

Cogent Biosciences (COGT) stock is in focus after the company released updated APEX trial data for bezuclastinib in advanced systemic mastocytosis, along with preclinical results for JAK2 V617F inhibitor CGT1145 at the 2026 EHA Congress. See our latest analysis for Cogent Biosciences. The latest APEX and CGT1145 data arrive as Cogent Biosciences trades at US$33.67, with recent momentum reflected in a 7.3% 7 day share price return. The 1 year total shareholder return of about 4.7x highlights...
Seeking Alpha • Jun 14

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

Summary Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications with strong clinical data. COGT holds $866.4 million in cash, supporting operations through 2028 and enabling launches in systemic mastocytosis and GIST, mitigating near-term financing risk. Bezuclastinib has demonstrated robust efficacy in nonadvanced and advanced systemic mastocytosis and second-line GIST, with three regulatory filings and positive pivotal trial results. Despite stretched valuation metrics, I see COGT as an attractive opportunity for investors willing to accept regulatory and launch risk, given its maturing clinical and commercial profile. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data

Summary Bezuclastinib is COGT’s main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT’s SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its main catalyst this year. Bezuclastinib could target an aggregate TAM of up to $2.5 billion across NonAdvSM, AdvSM, and GIST, which dwarves its current market cap. The company also has a solid cash runway of about 1.9 years and should be sufficient until we see its main catalyst play out. This is why I think the recent 34% decline is actually a good speculative “Buy” opportunity for investors betting on Bezuclastinib’s 2025 upcoming data. Read the full article on Seeking Alpha
Seeking Alpha • Jun 23

Cogent Biosciences: Inflection Year Directly Ahead

Summary Today, we revisit clinical stage biotech firm Cogent Biosciences for the first time since 2022. The company is heading into the potential inflection year in 2025 and top line results from three late-stage trials should be out during the year. Cogent Biosciences is also well funded and enjoys solid support from the analyst community. An updated analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 14

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst

Summary Cogent Biosciences, Inc. has entered into a securities purchase agreement for a private investment in public equity financing, expected to raise approximately $225 million. The financing was led by Commodore Capital and a large investment management firm, with participation from several notable biotech investment firms. The funds will be used for research and development, activities related to bezuclastinib, the company's lead candidate. The hope is that bezuclastinib can secure approval to treat advanced and non-advanced systemic mastocytosis - a >$2bn potential market. There is a major data catalyst upcoming, when the company announces Phase 2 data from its SUMMIT study in non-advSM. Blueprint medicines Ayvakit is already approved in this indication, and bezuclastinib must show superiority to this drug. If it can, the share price may soar again. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Cogent Biosciences: What's Ahead

Summary Today, we put Cogent Biosciences, Inc. in the spotlight for the first time in nearly two years. Cogent stock has roughly tripled since positive trial data came out in June, and the company has addressed its current funding needs. More upside ahead? An investment analysis follows in the paragraphs below. A story only matters, I suspect, to the extent that the people in the story change.”― Neil Gaiman We circle back on Cogent Biosciences, Inc. (NASDAQ:COGT) today for the first time since our last piece on this company in October of 2020. At the time, the company was called Unum Therapeutics. Through a merger with privately held Kiq Bio soon thereafter, the company was reborn as Cogent Biosciences. So, is this newly born biotech concern a butterfly or a moth in relation to prospects for investors? An analysis follows below. Seeking Alpha Company Overview: Cogent Biosciences Inc. is based just outside of Boston in Cambridge, MA. This clinical stage biotech concern is focused on developing precision therapies for genetically defined diseases. Its stock currently trades around $17.00 a share and sports an approximate market capitalization of $1.1 billion. The company lead drug candidate is bezuclastinib. The compound is designed to target exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. When this mutation remains in a perpetual "on" state, it causes mast cells to accumulate in various internal organs including the bone marrow. This leads to an Orphan Disease called Systemic Mastocytosis. Other Exon 17 mutations have been found in other afflictions such as advanced Gastrointestinal Stromal Tumors, or GIST. Bezuclastinib is a highly selective and potent KIT inhibitor that eventually could lead to effective treatments for these indications. June Company Presentation Bezuclastinib is currently being evaluated in several studies. The company is currently enrolling patients in an ongoing two part Phase 2 trial called "Apex." This study is evaluating bezuclastinib to treat patients with Advanced Systemic Mastocytosis (AdvSM). This is a rare, very aggressive form of Systemic Mastocytosis. The average lifespan of someone with this rare affliction is 3.5 years. The company posted encouraging interim results from this study on June 10th, which helped ignite a big rally in the stock since then. June Company Presentation Cogent is also currently enrolling patients in a study called Summit. This is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of bezuclastinib in patients with Nonadvanced Systemic Mastocytosis or NonAdvSM. This is a life-long illness with chronic symptoms that occurs in approximately 90% of the people that have Systemic Mastocytosis. June Company Presentation Finally, the company is evaluating bezuclastinib as a potential treatment for GIST. These tumors are categorized by uncontrolled cell growth in the tissues of the gastrointestinal tract. Approximately 80% of GIST patients’ tumors are the result of primary KIT mutations. Bezuclastinib has studied in an 18 person Phase 1/2 trial both as monotherapy as well as part of a combination therapy with sunitinib. Median progression free survival [PFS] reached 11 months with these patients, most of these which were heavily treated previously. Currently approved therapies currently inhibit a subset of these mutations, but most patients develop resistance due to additional secondary KIT mutations, including mutations in Exon 17. Bezuclastinib is designed to inhibit the primary mutation while sunitinib looks to inhibit additional mutations.
Seeking Alpha • Jun 26

Cogent Biosciences: APEX Data Was Interesting, But We Need More

Cogent has a single molecule in various trials. Recently, they produced some positive early data. We should be able to get a better grasp on the company in about a year.

Rendement voor aandeelhouders

COGTUS BiotechsUS Markt
7D1.8%2.3%0.8%
1Y321.8%42.3%20.2%

Rendement versus industrie: COGT overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 42.3 % opleverde.

Rendement versus markt: COGT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 20.2 %.

Prijsvolatiliteit

Is COGT's price volatile compared to industry and market?
COGT volatility
COGT Average Weekly Movement5.0%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stabiele aandelenkoers: COGT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van COGT is het afgelopen jaar gedaald van 18% naar 5%.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
n/a258Andy Robbinswww.cogentbio.com

Cogent Biosciences, Inc, een biotechnologiebedrijf in een klinische fase, richt zich op de ontwikkeling van precisietherapieën voor genetisch bepaalde ziekten. De belangrijkste productkandidaat is bezuclastinib (CGT9486), een selectieve tyrosinekinaseremmer in Fase 3 van het onderzoek, ontworpen om mutaties in het KIT receptor tyrosinekinase aan te pakken, waaronder de KIT D816V mutatie die systemische mastocytose veroorzaakt, evenals andere mutaties in KIT exon 17, die worden aangetroffen bij patiënten met vergevorderde gastro-intestinale stromale tumoren. Het bedrijf ontwikkelt ook CGT4859, een reversibele en selectieve fibroblast-groeifactor receptor 2 remmer in Fase 1 studie voor patiënten met gedocumenteerde FGFR-mutaties, waaronder gevorderd cholangiocarcinoom; CGT4255, een nieuw ErbB2-mutantenprogramma, dat zich richt op bruikbare en ondergewaardeerde mutaties in vaste tumor systemische en CNS betrokken indicaties; en CGT6297, een nieuwe PI3Ka mutant-selectieve remmer.

Cogent Biosciences, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Cogent Biosciences zich tot de beurswaarde?
COGT fundamentele statistieken
MarktkapitalisatieUS$6.61b
Inkomsten(TTM)-US$354.30m
Inkomsten(TTM)n/a
0.0x
P/S-verhouding
-19.0x
Koers/Winstverhouding

Is COGT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
COGT resultatenrekening (TTM)
InkomstenUS$0
Kosten van inkomstenUS$0
BrutowinstUS$0
Overige uitgavenUS$354.30m
Inkomsten-US$354.30m

Laatst gerapporteerde inkomsten

Mar 31, 2026

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-2.07
Brutomarge0.00%
Nettowinstmarge0.00%
Schuld/Eigen Vermogen Verhouding36.7%

Hoe presteerde COGT op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/07/06 09:58
Aandelenkoers aan het einde van de dag2026/07/06 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Cogent Biosciences, Inc. wordt gevolgd door 21 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Colleen KusyBaird
David LebowitzCitigroup Inc
Kelsey GoodwinGuggenheim Securities, LLC